Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

Introduction Relapses in ANCA-associated vasculitis (AAV) increase the incidence of end-organ damage and their prevention requires prolonged immunosuppressive therapy. Rituximab, a type I anti-CD20 B cell depleting monoclonal antibody, is the current standard of care for induction of disease remissi...

Full description

Saved in:
Bibliographic Details
Main Authors: Simon Bond, Rachel B Jones, Rona M Smith, Kim Mynard, David R Jayne, Matthew Coates, Dominic Paul McGovern, Mark E McClure, Marcos Martinez Del Pero, Jacinta Lee, Menna Ruth Clatworthy
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/7/e083277.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/7/e083277.full

Similar Items